Concordance of Imaging and Pathology Diagnosis of Extranodal Tumour Deposits

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age16+
SponsorImperial College London

About this trial

Any patient with a suspected primary adenocarcinoma of the colon, sigmoid or rectum undergoing surgery are eligible. The date of surgery must be known prior to registration. This trial aims to determine if image mapping techniques can improve the concordance between imaging and pathology detection of tumour deposits. Lymph nodes and tumour deposits will be identified on pre-operative scans and mapped by radiologists then shared with pathologists prior to processing the resected specimen. Patients will be managed at their local hospital with standard follow-up. Patients will be followed up for 5 years.

Eligibility criteria

Qualifiers

Suspected primary adenocarcinoma of the colon, sigmoid or rectum (proven by biopsy taken as part of routine clinical practice, patients to be withdrawn if not subsequently adenocarcinoma on pathology).

Amenable to surgical resection.

Disease spread assessed on imaging

Patients having primary surgery and those undergoing neoadjuvant treatment will be included.

Disqualifiers

Patients with recurrent tumours

Synchronous tumours

Under the age of 16 years

Unable to give informed consent.

Trial design

Treatments tested in this trial

  • MRI mapping to guide pathological sampling of extranodal tumour deposits

Treatment groups

200 Participants
are divided into 1 treatment group

Sponsors and collaborators

Imperial College London

Lead sponsor

Pelican Cancer Foundation

Collaborator